AbbVie acquired Syndesi Therapeutics SA for $130 million upfront, a transaction completed in February 2022, structured as cash upfront plus contingent milestones.
Syndesi Therapeutics SA operates in Neuroscience, is based in Belgium. AbbVie acquired Syndesi and its portfolio of novel modulators of the synaptic vesicle protein 2A, including lead molecule ABBV-552 (formerly SDI-118). ABBV-552 is a small molecule evaluated to target nerve terminals and enhance synaptic efficiency. AbbVie made a $130 million upfront payment, recorded as acquired IPR&D, and accounted for it as an asset acquisition.
Adds an early-stage neuroscience asset targeting synaptic function to AbbVie's pipeline.
Advisory firms were not disclosed for this transaction.